151 related articles for article (PubMed ID: 21942302)
1. Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma.
Hollenbeak CS; Nikkel LE; Schaefer EW; Alemao E; Ghahramani N; Raman JD
J Manag Care Pharm; 2011 Oct; 17(8):610-20. PubMed ID: 21942302
[TBL] [Abstract][Full Text] [Related]
2. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of renal cell carcinoma among older adults in the targeted therapy era.
Kale HP; Mays DP; Nadpara PA; Slattum PW; Paul AK; Carroll NV
Urol Oncol; 2019 Jun; 37(6):356.e19-356.e28. PubMed ID: 30846388
[TBL] [Abstract][Full Text] [Related]
4. Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II-An Updated Analysis of SEER-Medicare Data.
Shih YT; Xu Y; Chien CR; Kim B; Shen Y; Li L; Geynisman DM
Pharmacoeconomics; 2019 Dec; 37(12):1495-1507. PubMed ID: 31286464
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.
Sundaram M; Song Y; Rogerio JW; Zhang S; Bhattacharya R; Adejoro O; Carley C; Zhu JJ; Signorovitch J; Haas NB
J Manag Care Spec Pharm; 2022 Oct; 28(10):1149-1160. PubMed ID: 36048895
[No Abstract] [Full Text] [Related]
6. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
[TBL] [Abstract][Full Text] [Related]
7. Healthcare costs and resource utilization associated with renal cell carcinoma among older Americans: A longitudinal case-control study using the SEER-Medicare data.
Bhandari NR; Kale HP; Carroll NV; McAdam-Marx C; Ounpraseuth ST; Tilford JM; Kamel MH; Kent EE; Payakachat N
Urol Oncol; 2022 Jul; 40(7):347.e17-347.e27. PubMed ID: 35643842
[TBL] [Abstract][Full Text] [Related]
8. Economic burden of renal cell carcinoma in the US: Part II--an updated analysis.
Shih YC; Chien CR; Xu Y; Pan IW; Smith GL; Buchholz TA
Pharmacoeconomics; 2011 Apr; 29(4):331-41. PubMed ID: 21395352
[TBL] [Abstract][Full Text] [Related]
9. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
[TBL] [Abstract][Full Text] [Related]
10. The burden of illness associated with renal cell carcinoma in the United States.
Lang K; Danchenko N; Gondek K; Schwartz B; Thompson D
Urol Oncol; 2007; 25(5):368-75. PubMed ID: 17826652
[TBL] [Abstract][Full Text] [Related]
11. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.
Davis KL; Mitra D; Kotapati S; Ibrahim R; Wolchok JD
Appl Health Econ Health Policy; 2009; 7(1):31-41. PubMed ID: 19558193
[TBL] [Abstract][Full Text] [Related]
12. Attributable costs of differentiated thyroid cancer in the elderly Medicare population.
Boltz MM; Hollenbeak CS; Schaefer E; Goldenberg D; Saunders BD
Surgery; 2013 Dec; 154(6):1363-9; discussion 1369-70. PubMed ID: 23973115
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
Griffiths RI; Barron RL; Gleeson ML; Danese MD; O'Hagan A; Chia VM; Legg JC; Lyman GH
Pharmacoeconomics; 2012 Feb; 30(2):103-18. PubMed ID: 21967155
[TBL] [Abstract][Full Text] [Related]
14. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
[TBL] [Abstract][Full Text] [Related]
15. Disease-related and all-cause health care costs of elderly patients with gout.
Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
[TBL] [Abstract][Full Text] [Related]
16. Medical care costs and survival associated with hepatocellular carcinoma among the elderly.
White LA; Menzin J; Korn JR; Friedman M; Lang K; Ray S
Clin Gastroenterol Hepatol; 2012 May; 10(5):547-54. PubMed ID: 22210536
[TBL] [Abstract][Full Text] [Related]
17. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
[TBL] [Abstract][Full Text] [Related]
18. Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma.
Li P; Jahnke J; Pettit AR; Wong YN; Doshi JA
JAMA Netw Open; 2019 Jun; 2(6):e195806. PubMed ID: 31199450
[TBL] [Abstract][Full Text] [Related]
19. Determinants of Medicare Costs for Elderly Patients With Oral Cavity and Pharyngeal Cancers.
Hollenbeak CS; Kulaylat AN; Mackley H; Koch W; Schaefer EW; Goldenberg D
JAMA Otolaryngol Head Neck Surg; 2015 Jul; 141(7):628-35. PubMed ID: 26042925
[TBL] [Abstract][Full Text] [Related]
20. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.
McAdam-Marx C; McGarry LJ; Hane CA; Biskupiak J; Deniz B; Brixner DI
J Manag Care Pharm; 2011 Sep; 17(7):531-46. PubMed ID: 21870894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]